What we do
Who we serve
With a revenue of more than $48 billion and ranked 76th on the Fortune 500 list, Merck and Company has proven its ability to maintain an impressive level of success for more than 125 years. With its core focus being on vaccines and therapeutic medicine, this pharmaceutical innovator looks to not just save, but also improve millions of lives all over the world.
Today, Continuant maintains all of Merck’s Avaya systems, and has done so since 2016. Merck knows that working with Continuant also means that there will be “no pressure to upgrade” its Avaya systems and that Continuant will offer the best solutions for Merck, based on the company’s needs.
In addition, Merck cites both the high level of service and the cost-saving benefits of working with Continuant. Merck has realized a 60 percent cost savings over the OEM by having Continuant maintain and support its Avaya systems.
To support this global medical mission, Merck had more than 30,000 users on an Avaya system. As with many Avaya customers, Merck began looking to implement a UC solution. To complete this transition, it needed the proper insight and support, something it worried Avaya would be unable, or rather, unwilling to provide. Seeking the counsel of other pharmaceutical companies, a source at Bayer Corporation (a Continuant customer since 2007) set them in the right direction.
Merck will be migrating to a Cisco Unified Communications solution over the next several years, and Continuant is positioned to offer world-class Managed Services for Cisco UC.